– Evaluation of nimotuzumab Fab2 as an optical imaging agent in EGFR positive cancers. Sci Rep. 2023 Jul 7;13(1):10990.
– Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med 2023;389:205-214.
– Potential for Maternally Administered Vaccine for Infant Group B Streptococcus. N Engl J Med 2023;389:215-227.
– Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med 2023;389:239-250.
– Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2023; 388:2444-2455.
– Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell, 2023; https://doi.org/10.1016/j.cell.2023.06.002.
– FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. FDA, July 06, 2023.
En la sección: Autoinmunidad, Autores cubanos en revistas extranjeras, Infectología, Inmunidad tumoral, Inmunoterapia, Vacunología. Publicado en: . 
